ALL INFORMATION IS FOR REFERENCE ONLY. PLEASE CONFIRM YOU ARE A PHARMACIST, DOCTOR, OR HEALTHCARE WORKER TO CONTINUE LEARNING ABOUT THIS PRODUCT!

IRBEPRO 150

RX : THIS DRUG IS FOR PRESCRIPTION ONLY
COMPOSITION : Active ingredient: Each film-coated tablet contains 150 mg of irbesartan.
Excipients: lactose monohydrate, cellulose microcrystalline, corn starch, polysorbate 80, povidone K30, anhydrous colloidal silica, croscarmellose sodium, magnesium stearate q.s.
PACKING : Box of 3 blisters x 10 tablets.
SHELF LIFE : 36 months from the manufacturing date.
INDICATIONS : Irbesartan is indicated in adults for the treatment of essential hypertension.
It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.
Posology and Method of Administration

The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Irbesartan Tablet at a dose of 150 mg once daily generally provides a better 24 hours blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.

In patients insufficiently controlled with 150 mg once daily, the dose of Irbesartan can be increased to 300 mg, or other antihypertensive agents can be added. In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Irbesartan.

In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.

The demonstration of renal benefit of Irbesartan in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure.

Special Populations

Renal impairment: No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis.

Hepatic impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment.

Elderly: Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for the older people.

Paediatric population: The safety and efficacy of Irbesartan in children aged 0 to 18 has not been established.

 

 

METHOD OF ADMINISTRATION

For oral use.

Ý kiến bạn đọc
Other product of ANGIOTENSIN II RECEPTOR BLOCKERS